Beneficial effects of fingolimod in MS patients with high serum Sema4A levels (original) (raw)
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
Sparsh Gupta
Journal of Pharmacology and Pharmacotherapeutics, 2011
View PDFchevron_right
Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
Hans-peter Hartung
Clinical Immunology, 2012
View PDFchevron_right
Fingolimod reduces the clinical expression of active demyelinating lesions in MS
Elisabetta Signoriello
Multiple Sclerosis and Related Disorders, 2018
View PDFchevron_right
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
Hans-peter Hartung
Neuropsychiatric Disease and Treatment, 2011
View PDFchevron_right
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod
Claudio Gasperini
Therapeutics and clinical risk management, 2013
View PDFchevron_right
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom
Augusto Grinspan
CNS Neuroscience & Therapeutics, 2014
View PDFchevron_right
Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions
Ludwig Kappos
Current neurology and neuroscience reports, 2011
View PDFchevron_right
Biomedical Journals The Effects of Fingolimod on T Cells and the Central Nervous System in the Pathogenesis of Multiple Sclerosis Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Samuel F Hunter
View PDFchevron_right
Roles of Sema4A in multiple sclerosis and interferon-β therapy efficacy
Josephe Honorat, Hideki Mochizuki, Kazushiro Takata
Clinical and Experimental Neuroimmunology, 2013
View PDFchevron_right
Japanese guidelines for fingolimod in multiple sclerosis: Putting into practice
Ichiro Nakashima
Clinical and Experimental Neuroimmunology, 2014
View PDFchevron_right
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
andreas billich
Nature Reviews Drug Discovery, 2010
View PDFchevron_right
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients
María Mansilla
CNS neuroscience & therapeutics, 2018
View PDFchevron_right
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach
Claudio Gasperini
Drug Design, Development and Therapy, 2012
View PDFchevron_right
Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
Nicolae Dandu
PLOS ONE, 2020
View PDFchevron_right
Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
Lixin Zhang-Auberson, Ernst-wilhelm Radue
Neurology, 2015
View PDFchevron_right
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Rana Karabudak
Journal of Neurology, Neurosurgery & Psychiatry, 2019
View PDFchevron_right
Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod
Claudio Gasperini
Therapeutics and Clinical Risk Management, 2013
View PDFchevron_right
Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study
Lixin Zhang-Auberson
BMC neurology, 2017
View PDFchevron_right
How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
Franz Fazekas
Frontiers in Neurology, 2013
View PDFchevron_right
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN- Therapy in Multiple Sclerosis
Makoto Kinoshita
The Journal of Immunology, 2012
View PDFchevron_right
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
Judith Fraussen
PLoS ONE, 2014
View PDFchevron_right
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
Peter Turcani
2012
View PDFchevron_right
Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study
Arianna Merlini
Multiple Sclerosis Journal, 2017
View PDFchevron_right
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy
Toshiki Mizuno
Scientific reports, 2016
View PDFchevron_right
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Sara Rizzoli
Neurological Sciences
View PDFchevron_right
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
Lauren Krupp
Journal of Neurology, Neurosurgery & Psychiatry, 2019
View PDFchevron_right
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients
Christian Sindic
PLoS ONE, 2014
View PDFchevron_right
Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis
Tatsuro Misu, Ichiro Nakashima
Journal of Neuroimmunology, 2014
View PDFchevron_right
Critical Appraisal of Effectiveness of Oral Fingolimod on Relapsing Multiple Sclerosis
rosa sanyasi
Journal of Pharmaceutical Sciences and Community, 2017
View PDFchevron_right
Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
Regina Alvarenga
Advances in therapy, 2015
View PDFchevron_right